News Conference News HFSA 2025 Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM Yael L. Maxwell October 01, 2025
News Conference News HFSA 2024 Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM L.A. McKeown October 04, 2024
News Conference News HFSA 2024 ‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM L.A. McKeown October 02, 2024
News Conference News HFSA 2024 FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone? Michael O'Riordan October 02, 2024
News Conference News HFSA 2023 Innovation in Heart Donation, Preservation Set to Shake Up Allocation Todd Neale October 18, 2023
News Conference News HFSA 2023 STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization L.A. McKeown October 18, 2023
News Conference News HFSA 2023 REBALANCE-HF Uncovers HFpEF Group That Responds to Splanchnic Nerve Ablation Todd Neale October 11, 2023
News Conference News HFSA 2023 Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis Todd Neale October 11, 2023
News Conference News HFSA 2022 No Benefit of LAA Ligation During HeartMate 3 Implantation: MOMENTUM 3 Yael L. Maxwell October 07, 2022
News Conference News HFSA 2022 New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented Todd Neale October 07, 2022
News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022
News Conference News HFSA 2021 Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF Michael O'Riordan September 14, 2021
News Conference News HFSA 2019 New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF L.A. McKeown September 18, 2019